AGENUS INC Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AGENUS INC stock issued during period, value, conversion of convertible securities for the quarter ending 2021-09-30 was $18.27M.
- AGENUS INC stock issued during period, value, conversion of convertible securities for the quarter ending 2021-06-30 was $4.32M.
- AGENUS INC stock issued during period, value, conversion of convertible securities for the quarter ending 2021-03-31 was $4.32M.
- AGENUS INC stock issued during period, value, conversion of convertible securities for the quarter ending 2019-06-30 was $6.48M.
- AGENUS INC stock issued during period, value, conversion of convertible securities for fiscal 2021 was $26.92M.
- AGENUS INC stock issued during period, value, conversion of convertible securities for fiscal 2019 was $12.96M.
- AGENUS INC stock issued during period, value, conversion of convertible securities for fiscal 2013 was $0.00.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2021-12-31 | $26.92M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $18.27M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $4.32M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $4.32M 10-Q · filed 2022-11-08 | |
| 2019-12-31 | $12.96M 10-K · filed 2022-03-01 | |
| 2019-06-30 | $6.48M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $6.48M 10-Q · filed 2020-11-09 | |
| 2013-12-31 | $0.00 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |